Skip to search formSkip to main contentSkip to account menu

SGI-110

Known as: DNMT inhibitor SGI-110, S110 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Azacitidineguadecitabine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
Introduction: The hypomethylating agents (HMA) are the standard of care for a majority of patients with higher-risk MDS. SGI… 
2018
2018
A Three‐Pronged Epigenetic Approach to the Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is among the fastest growing causes of cancer related death in the United States due to a lack of… 
2016
2016
Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2…
Introduction: Guadecitabine (SGI-110) is a novel next-generation hypomethylating agent (HMA) administered as a small volume… 
2016
2016
Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment
Background: Hypomethylating agents (HMAs) have become the reference treatment of higher risk MDS, but the median survival of… 
2015
2015
Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine…
![Graphic][1] Introduction: Guadecitabine (SGI-110) is a novel next-generation HMA administered as a small volume subcutaneous… 
Review
2014
Review
2014
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
Purpose A recent phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy is a new treatment… 
2014
2014
First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR…
![Graphic][1] Background: SGI-110 is a second generation HMA formulated as a dinucleotide of decitabine (DAC) and… 
2012
2012
Abstract LB-214: Interim results from a randomized Phase 1-2 first-in-human (FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent…
SGI-110 is a novel second generation HMA, formulated as a low volume SQ injection. It is designed as a dinucleotide incorporating… 
2011
2011
Complete Genome Sequence of the Metabolically Versatile Plant Growth-Promoting Endophyte Variovorax paradoxus S 110 ‡
Complete Genome Sequence of the Metabolically Versatile Plant Growth-Promoting Endophyte Variovorax paradoxus S110 ‡ Jong-In Han… 
2008
2008
Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat.
Lysine specific histone methylation and deacetylation and DNA hypermethylation are involved in the epigenetic silencing of tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)